Pfizer to receive up to $1.5bn in funding from Blackstone Life Sciences
The funding will be for a GLP-1 receptor agonist clinical programme for weight loss
Read More
The funding will be for a GLP-1 receptor agonist clinical programme for weight loss
Read MoreIf approved, it would be the only FDA-approved, oral, non-hormonal treatment for pattern hair loss in both male and female patients
Read MorePeople with the rare and debilitating genetic skin disorder have extremely fragile skin that is prone to blistering and wounds
Read MoreRemibrutinib reduced relapse rates and improved disease progression rates
Read MoreThere is currently no licensed vaccine for Strep A, despite it causing hundreds of millions of infections globally
Read MoreThe Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
Read MoreThe use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
Read MoreResults show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss
Read MoreNSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment
Read MoreThe new centre will be home to nearly 2,000 world-class researchers and scientists
Read MoreThe results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity
Read MoreThis builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
Read More
